Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE^® (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

"Teva and the COPAXONE^® team are honored to be acknowledged by Pharmaceutical Executive, a respected voice in our industry," said Mike Derkacz, Vice President, and General Manager of Teva CNS. "The award is a tribute to the hard work of Teva employees and scientists throughout the years; the growth of COPAXONE^® and the loyalty of prescribers and patients alike; and speaks to the product's benefits, tolerability and safety."

The "Brand of The Year" award was received on behalf of Teva by John Hassler, Vice President of Marketing for Teva CNS at an award ceremony hosted by Pharmaceutical Executive in New York. "For more than 20 years, Teva has consistently focused on making this brand an appropriate choice for many patients with relapsing forms of multiple sclerosis with rigorous clinical studies, product enhancements and patient support services like Shared Solutions^®. Our most recent and significant product development is the new FDA approved, three-times-a-week dose of COPAXONE^® 40mg. This honor is a testament to that work," he said.

COPAXONE^® was first approved for marketing by the U.S. FDA as a treatment for relapsing-remitting multiple sclerosis in 1996. Daily COPAXONE^® 20 mg/mL is approved in more than 50 countries worldwide, including the United States, all European countries, Israel, Canada, Mexico, Australia and Russia.

On January 28, 2014, Teva announced that the U.S. Food and Drug Administration approved the Company's supplemental new drug application (sNDA) for three-times-a-week COPAXONE^® 40 mg/mL, a new dose of COPAXONE^®. This new formulation allows for a less-frequent subcutaneous dosing regimen as compared to the COPAXONE^® 20 mg/mL daily dose option.